Table 2.
Clinical, pathologic, demographic, molecular characteristics, response to therapy, progression-free survival and overall survival in the studied patients
| Patient | Site | Age (yrs)/ Sex |
Histology | Smoking history |
Type of EGFR mutation |
Therapy prior to gefitinib |
Response - gefitinib 250 mg/d |
PFS - gefitinib (months) |
EGFR re- sequence |
MET amplification |
Therapy prior to erlotinib |
Response - erlotinib 150 mg/d |
PFS - erlotinib (months) |
Survival from gefitinib (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BIDMC | 71/M | Adeno | former (40 py) |
delL747- S752 |
platinum- doublet |
CR | 24 | delL747- S752 + T790M |
ND | cetuximab, experimental Raf inhibitor |
PD | 1 | 30 |
| 2 | BIDMC | 74/F | Adeno | never smoker |
L858R | platinum- doublet |
PR | 40 | L858R + L747S |
No | experimental EGFR inhibitor |
PR | 6 | >62 (alive)# |
| 3 | BIDMC | 75/F | Adeno | never smoker |
delE746- A750 |
none | PR | 26 | ND | ND | none | PD | 2 | 35 |
| 4 | BIDMC | 77/F | Adeno | never smoker |
L858R | none | PR | 14 | ND | ND | none | PD | 3 | 27 |
| 5 | YCC | 45/F | Adeno | never smoker |
delL747- 751InsP |
platinum- doublet |
PR | 16.5 | ND | ND | none | SD | 3.7 | 39 |
| 6 | YCC | 56/F | Adeno | never smoker |
delL747- 751InsP |
platinum- doublet |
PR | 12 | delL747- 751InsP + T790M |
No | none | PD | 2 | 19 |
| 7 | YCC | 47/M | Adeno | smoker | delE746- T751InsA |
platinum- doublet |
PD | 1 | ND | ND | none | PD | 2 | 3 |
| 8 | YCC | 49/F | Adeno | never smoker |
delL747- 751InsP |
platinum- doublet |
PR | 3 | ND | ND | none | PD | 2 | 16 |
| 9 | YCC | 70/M | Adeno | smoker | delE746- A750 |
platinum- doublet |
PD | 2 | ND | ND | none | PD | 2 | 7 |
| 10 | DFCI | 43/M | NSCLC -NOS |
never smoker |
L858R | none | PR | 4 | ND | ND | none | PD | 2 | 9 |
| 11 | MGH | 64/M | NSCLC -NOS |
former (30 py) |
L858R | none | PR | 4 | ND | ND | none | PD | 2 | 21 |
| 12 | MGH | 64/F | Adeno | never smoker |
delE746- A750 |
none | PR | 7 | ND | ND | experimental Hsp90 inhibitor |
PD | 1 | >20 (alive)# |
| 13 | MGH | 69/F | Adeno | former (20 py) |
L861Q | none | SD | 4 | ND | ND | none | PD | 2 | 9 |
| 14 | MGH | 60/F | Adeno | former (5 py) |
delE746- A750 |
none | PR | 17 | ND | ND | none | SD | 5 | >49 (alive)# |
| 15 | MSKCC | 60/M | Adeno | never smoker |
delE746- A750 |
platinum- doublet |
PR | 16 | delE746- A750 + T790M* |
ND | none | PD | 4 | 32 |
| 16 | MSKCC | 52/F | Adeno | never smoker |
delE746- A750 |
platinum- doublet |
PR | 10 | delE746- A750 + T790M* |
ND | none | PD | 3 | >39 (alive)# |
| 17 | MSKCC | 62/F | Adeno | never smoker |
delE746- A750 |
platinum- doublet |
PR | 11 | delE746- A750 + T790M* |
ND | none | SD | 6 | >44 (alive)# |
| 18 | MSKCC | 80/M | Adeno | former (2 py) |
delE746- A750 |
none | SD | 11 | delE746- A750 + T790M* |
No* | none | PD | 2 | 32 |
BIDMC, Beth Israel Deaconess Medical Center; YCC, Yonsei Cancer Center; DFCI; Dana-Farber Cancer Institute; MGH, Massachussetss General Hospital; MSKCC, Memorial Sloan-Kettering Cancer Center; Adeno, adenocarcinoma; NSCLC-NOS, non-small cell lung cancer-not otherwise specified; EGFR, epidermal growth factor receptor; M, male; F, female; py, pack-years; Del 19, exon 19 deletion; ND, not done; CR, complete response; PR, partial response; PD, progressive disease; SD, stable disease; TTP, time to progression; yrs, years; Hsp90, heat shock protein 90;
EGFR re-sequence and/or MET amplification was obtained after exposure to gefitinib and erlotinib
latest survival data collected June 1st, 2008.